Cardiovascular complications of ribociclib in breast cancer patients

Oraianthi Fiste; Evangelos Mavrothalassitis; Kleoniki Apostolidou; Chrysanthi Trika; Michalis Liontos; Konstantinos Koutsoukos; Maria Kaparelou; Constantine Dimitrakakis; Maria Gavriatopoulou; Meletios A Dimopoulos; Flora Zagouri

doi:10.1016/j.critrevonc.2024.104296

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2003

Complications of chronic venous access devices in cancer patients.

Giancarlo Agnelli

Article2016

Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer

Ioannis Kapelakis, Konstantinos Toutouzas, Maria Drakopoulou, Archontoula Michelongona, Flora Zagouri, Aristotle Mpamias, Paraskevi Pliatsika, Meletios A Dimopoulos, Christodoulos Stefanadis, Dimitrios Tousoulis

Preprint2025

Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control Study

Oraianthi Fiste, Martina Samiotaki, Efstathios Manios, Chrysanthi Trika, Christine‐Ivy Liacos, Constantine Dimitrakakis, Meletios A Dimopoulos, Maria Gavriatopoulou, Flora Zagouri

Article2025

Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study

Oraianthi Fiste, Martina Samiotaki, Efstathios Manios, Chrysanthi Trika, Christine‐Ivy Liacos, Constantine Dimitrakakis, Meletios A Dimopoulos, Maria Gavriatopoulou, Flora Zagouri

Article2021

Cardiovascular toxicity of breast cancer treatment: an update

Christos Papageorgiou, Αngeliki Andrikopoulou, Meletios A Dimopoulos, Flora Zagouri